AC
PTCT icon

Axon Capital’s PTC Therapeutics PTCT Stock Holding History

Axon Capital’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		$6.73M Sell
199,100
-17,100
-8% -$744K 17.97% 1
2019
Q2 		$9.73M Buy
216,200
+50,400
+30% +$1.99M 20.31% 1
2019
Q1 		$6.24M Buy
+165,800
New +$5.57M 13.11% 6

Other funds holding PTCT

Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return

Axon Capital's PTCT Position: Q3 2019 in Review

Axon Capital reduced its PTC Therapeutics (PTCT) stake by 7.9% in Q3 2019, selling an estimated $744K and leaving 199,100 shares worth $6.73M. The position accounts for 17.97% of the portfolio, ranked #1.

Axon Capital first reported a position in PTCT in Q1 2019 and has held it in 3 quarters since. The position peaked at $9.73M in Q2 2019. 184 funds tracked by Wall St. Rank hold PTCT as of Q3 2019.

  • Axon Capital held 199,100 shares of PTC Therapeutics worth $6.73M as of Q3 2019.
  • Axon Capital sold 17,100 PTC Therapeutics shares in Q3 2019, an estimated $744K.
  • PTC Therapeutics made up 17.97% of Axon Capital's portfolio in Q3 2019, its #1 holding.
  • Axon Capital first reported a position in PTC Therapeutics in Q1 2019 and has held it in 3 quarters since.
  • Axon Capital's PTC Therapeutics position peaked at $9.73M in Q2 2019.
  • 184 funds tracked by Wall St. Rank held PTC Therapeutics as of Q3 2019.

Based on Axon Capital's 13F filing for Q3 2019, filed 14 Nov 2019.